Know Cancer

or
forgot password

The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men


Phase 4
55 Years
85 Years
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men


Inclusion Criteria:



- Non-metastatic prostate cancer

- Men to receive GnRH-agonist therapy

Exclusion Criteria:

- Other cancers except skin cancer

- Evidence of metabolic bone disease

- Prior use of bisphosphonates

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Bone mineral density

Outcome Time Frame:

6 and 12 months

Safety Issue:

No

Principal Investigator

Pamela Taxel, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Connecticut Health Center

Authority:

United States: Institutional Review Board

Study ID:

02-062

NCT ID:

NCT00859027

Start Date:

January 2003

Completion Date:

February 2009

Related Keywords:

  • Prostate Cancer
  • Non-metastatic
  • Prostatic Neoplasms

Name

Location
University of Connecticut Health Center Farmington, Connecticut  06360-7106